NR1D2 deficiency has been reported to inhibit the proliferation of hepatocellular carcinoma and glioblastoma cancer cells, indicating that NR1D2 has oncogenic potential [55, 56]. Here, NR1D2 is linked to hepatocellular carcinoma.